Copyright © 2016

Aridis Pharmaceuticals, Inc.

5941 Optical Court, San Jose, CA 95138

Phone: 408-385-1742

Site Map

Privacy Policy

Financial Conflict of Interest Policy

Back to top

Previous page



Aridis Pharmaceuticals, Inc. Appoints Alan H. Cohen, MD, as Senior Vice President of Clinical & Medical Affairs.


Aridis Pharmaceuticals Enrolls First Patients in Global Pivotal Clinical Trial of Novel Monoclonal Antibody for Treating Acute Pneumonia.


Aridis Pharmaceuticals, Inc. Presents Positive Phase 2a Safety and Efficacy Data of SalvecinTM (AR-301) in Patients with Severe Pneumonia Caused by Staphylococcus aureus During the 2017 ASM Microbe Congress.


Aridis Pharmaceuticals Reports Positive Clinical Data from Phase 1/2a Study of Human Monoclonal Antibody AR-301 for Treating Pneumonia.


Aridis Pharmaceuticals CEO Invited to Speak on Infectious Disease Panel at 2016 Anti-Infectives Rx Conference.


Aridis Pharmaceuticals Expands the Company’s Clinical Advisory Board; Adds Three Industry Veterans with Unique Expertise in the Field.

Immunotherapy Using Monoclonal Antibodies is the Next Frontier in Fighting Infections
Featured Product

The biggest threat to global health today is antibiotic resistance. Aridis’ solution is to leverage the natural human immune system in the form of monoclonal antibodies to fight infections. This novel approach is also referred to as anti-infective immunotherapy.

We have developed a broad, unrivaled portfolio of anti-infective monoclonal antibodies or mAbs that target the infecting pathogens.  Aridis has three of the most advanced monoclonal antibodies that are in Phase 2 and pivotal clinical trials to address the $30B antibiotic resistance market.

Our mAb therapies are complemented by a breakthrough discovery platform called MabIgX that allows for discovery of rare, protective antibody producing B-cells and the rapid transition to clinical testing.    

AR-301 (SalvecinTM) is a fully human monoclonal IgG1 antibody specifically targeting S. aureus alpha-toxin. Upon binding to its target antigen AR-301 represses functional toxin pore formation leading to protection of susceptible cells of the infected host from alpha-toxin dependent destruction. Its mode of action is independent of the antibiotic resistance profile of S. aureus, hence AR-301 is active against infections caused by both antibiotic resistant (MRSA) and antibiotic sensitive (MSSA) strains. Intravenous administration of AR-301 mAb to mice with acute pneumonia caused by S. aureus resulted in reduced bacterial loads and significantly improved survival rates. Aridis reported positive results from an international Phase 1/2a human clinical trial evaluating AR-301 in hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) patients. VABP patients treated with antibiotics plus AR-301 at all dose levels spent a shorter time under mechanical ventilation as compared to antibiotics plus placebo. Eradication of S. aureus was also consistently higher in the group receiving AR-301 at all dose levels. The Company will move forward with plans for late-stage clinical studies of AR-301 in 2017.

More >>

More >>

More >>


Breakthrough Therapies for

Antibiotic Resistant Infections

Aridis Home